Evidence map›Paper›PMID 21818392›Full record

ArticlePloS one2011

Progressive reduction of its expression in rods reveals two pools of arrestin-1 in the outer segment with different roles in photoresponse recovery.

Whitney M Cleghorn, Elviche L Tsakem, Xiufeng Song, Sergey A Vishnivetskiy, Jungwon Seo, Jeannie Chen, Eugenia V Gurevich, Vsevolod V Gurevich

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Arrestin mutations: Some cause diseases, others promise cure.Progress in molecular biology and translational science · 2019
    Review
  2. Article
  3. Molecular Defects of the Disease-Causing Human Arrestin-1 C147F Mutant.Investigative ophthalmology & visual science · 2018
    Article
  4. Analyzing the roles of multi-functional proteins in cells: The case of arrestins and GRKs.Critical reviews in biochemistry and molecular biology · 2015
    Review
  5. Enhanced phosphorylation-independent arrestins and gene therapy.Handbook of experimental pharmacology · 2014
    Article
  6. Arrestins in apoptosis.Handbook of experimental pharmacology · 2014
    Article
  7. Article
  8. Article
  9. Structural determinants of arrestin functions.Progress in molecular biology and translational science · 2013
    Review
  10. Article
  11. The functional cycle of visual arrestins in photoreceptor cells.Progress in retinal and eye research · 2011
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Whitney M CleghornDepartment of Pharmacology, Vanderbilt University, Nashville, Tennessee, United States of America.
Elviche L Tsakem
Xiufeng Song
Sergey A Vishnivetskiy
Jungwon Seo
Jeannie Chen
Eugenia V Gurevich
Vsevolod V Gurevich
Vanderbilt University · USUniversity of Southern California · US

Funding

Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 1989 to 2026
$19.6M
STRUCTURE/FUNCTION STUDIES OF VISUAL ARRESTINR01EY011500 · NEI · VANDERBILT UNIVERSITY · PI T M Iverson · 1997 to 2026
$12.3M
Phototransduction in health and diseaseR01EY012155 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Jeannie Chen · 1998 to 2026
$11.8M
Training in Vision ResearchT32EY007135 · NEI · VANDERBILT UNIVERSITY · PI GEOFFREY F WOODMAN · 1994 to 2026
$5.8M
Arrestin interactions with non-receptor binding partnersR01GM077561 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2007 to 2015
$2.3M
Signaling regulation in the striatum in Parkinson's diseaseR01NS065868 · NINDS · VANDERBILT UNIVERSITY · PI GUREVICH, EUGENIA V · 2009 to 2013
$1.7M
Dopamine Receptor Trafficking in Parkinson's DiseaseR01NS045117 · NINDS · VANDERBILT UNIVERSITY · PI GUREVICH, EUGENIA V · 2003 to 2007
$1.6M
Conformational regulation of arrestin-mediated signalingR01GM081756 · NIGMS · VANDERBILT UNIVERSITY · PI GUREVICH, VSEVOLOD V. · 2008 to 2011
$1.5M
NEI NIH HHS EY011500NEI NIH HHS EY012155NEI NIH HHS P30 EY008126NEI NIH HHS R01 EY011500NEI NIH HHS R01 EY012155NEI NIH HHS T32 EY007135NEI NIH HHS T32 EY07135NIGMS NIH HHS GM077561NIGMS NIH HHS GM081756NIGMS NIH HHS R01 GM077561NIGMS NIH HHS R01 GM081756NINDS NIH HHS NS045117NINDS NIH HHS NS065868NINDS NIH HHS R01 NS045117NINDS NIH HHS R01 NS065868
6 · The paper itself

Abstract

Light-induced rhodopsin signaling is turned off with sub-second kinetics by rhodopsin phosphorylation followed by arrestin-1 binding. To test the availability of the arrestin-1 pool in dark-adapted outer segment (OS) for rhodopsin shutoff, we measured photoresponse recovery rates of mice with arrestin-1 content in the OS of 2.5%, 5%, 60%, and 100% of wild type (WT) level by two-flash ERG with the first (desensitizing) flash at 160, 400, 1000, and 2500 photons/rod. The time of half recovery (t(half)) in WT retinas increases with the intensity of the initial flash, becoming ∼2.5-fold longer upon activation of 2500 than after 160 rhodopsins/rod. Mice with 60% and even 5% of WT arrestin-1 level recovered at WT rates. In contrast, the mice with 2.5% of WT arrestin-1 had a dramatically slower recovery than the other three lines, with the t(half) increasing ∼28 fold between 160 and 2500 rhodopsins/rod. Even after the dimmest flash, the rate of recovery of rods with 2.5% of normal arrestin-1 was two times slower than in other lines, indicating that arrestin-1 level in the OS between 100% and 5% of WT is sufficient for rapid recovery, whereas with lower arrestin-1 the rate of recovery dramatically decreases with increased light intensity. Thus, the OS has two distinct pools of arrestin-1: cytoplasmic and a separate pool comprising ∼2.5% that is not immediately available for rhodopsin quenching. The observed delay suggests that this pool is localized at the periphery, so that its diffusion across the OS rate-limits the recovery. The line with very low arrestin-1 expression is the first where rhodopsin inactivation was made rate-limiting by arrestin manipulation.

Indexed as

LightAnimalsArrestinLight Signal TransductionMiceRod Cell Outer SegmentTime FactorsArrestin

Identifiers

PMID21818392
PMCPMC3144249
OpenAlexW2092436277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.